Trial reportBMC neurology2025
The efficacy of levodopa/carbidopa/entacapone on cognitive function in moderate to advanced Parkinson's disease and its relationship with peripheral inflammatory cytokines.
Trial report in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Trial
- Sleep Disturbances and Non-REM Phase Alterations in Children with Celiac Disease: A Combined Questionnaire and EEG Study.Brain sciences · 2026Article
- CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's Disease.Research square · 2025Article
- Therapeutic potential of transcutaneous auricular vagus nerve stimulation in cognitive impairment: insights from preclinical and clinical studies.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEntacapone has been widely used in the treatment of moderate to advanced Parkinson's disease (PD), and its efficacy for motor symptoms has been well-known from several clinical trials and long-term clinical use. The efficacy of Levodopa/Carbidopa/Entacapone (LCE) on neuropsychological functions in moderate to advanced PD has not been validated yet, and little is known about the effect of LCE on peripheral inflammatory cytokines.
objectivesThe aim of this study was to investigate the efficacy of LCE on neuropsychological functions in moderate to advanced PD and to explore its relationship with the changes in peripheral inflammatory cytokine levels.
methodsAll patients were randomly assigned to the experimental group receiving treatment of LCE or the control group receiving treatment of Levodopa/Carbidopa (LC). All patients were clinically evaluated using the Unified Parkinson's Disease Rating Scale part III (UPDRS III), the total score of the Parkinson's Disease Questionnaire-39 (PDQ-39), the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Hamilton Anxiety Scale (HAMA), and the Hamilton Depression Scale (HAMD), and serum homocysteine (HCY) as well as serum inflammatory cytokines were measured at baseline and after 8 weeks.
resultsThe moderate to advanced PD patients treated with LCE had more significant improvement in MMSE scores (P = 0.004) and MoCA scores (P = 0.001), as well as a greater decline in IL-6 levels (P = 0.002) than those treated with LC. There were no significant differences in the changes of the UPDRS III, PDQ39, HAMA, and HAMD scores between the two treatment groups. Linear correlation analysis revealed that there was a significant negative correlation between the improvement of MoCA scores (ΔMoCA) and the reduction of IL-6 levels (ΔIL-6) (correlation coefficient: -0.252; P = 0.024).
conclusionsThe ability of LCE to improve cognitive function and to downregulate the peripheral inflammatory cytokine IL-6 levels in moderate to advanced PD is superior to the traditional dopamine preparation-LC. LCE may improve cognitive function by suppressing the levels of inflammatory cytokines like IL-6.
trial registrationThe full name of the registry: Dongyang People's Hospital, Affiliated to Wenzhou Medical University. The trial registration number (TRN): ChiCTR2400091631. The date of registration: October 31, 2024 (Retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.